Microparticle-based technologies for vaccines

被引：123

作者：

O'Hagan, Derek T. ^{[1
]}

Singh, Manmohan ^{[1
]}

Ulmer, Jeffrey B. ^{[1
]}

机构：

[1] Novartis Vaccines & Diagnost Inc, Vaccines Res, Emeryville, CA 94608 USA

来源：

METHODS | 2006年 / 40卷 / 01期

关键词：

adjuvants; delivery systems; innate immunity; toll-like receptors; antibodies; helper T lymphocytes; cytotoxic T lymphocytes;

D O I：

10.1016/j.ymeth.2006.05.017

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Microparticles have been effectively used for many years as delivery systems for drugs and therapeutic proteins. Their application to the delivery of vaccines is not as extensive, but is growing. Utility has been demonstrated for the delivery of various types of vaccines (e.g., recombinant proteins, plasmid DNA, and peptides) and other vaccine components (e.g., immune potentiators). With respect to delivery of immune potentiators, synergistic effects are often observed whereby much more potent immune responses are induced with a combination than with either component alone. Hence, the prospects for broad application of microparticle-based delivery systems for vaccines are excellent. (c) 2006 Elsevier Inc. All rights reserved.

引用

页码：10 / 19

页数：10

共 133 条

[1] Protective immunity against Salmonella typhimurium elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly(DL-lactide-co-glycolide) microspheres [J].

AllaouiAttarki, K ;

Pecquet, S ;

Fattal, E ;

Trolle, S ;

Chachaty, E ;

Couvreur, P ;

Andremont, A .

INFECTION AND IMMUNITY, 1997, 65 (03) :853-857

[2] Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children:: randomised controlled trial [J].

Alonso, PL ;

Sacarlal, J ;

Aponte, JJ ;

Leach, A ;

Macete, E ;

Milman, J ;

Mandomando, I ;

Spiessens, B ;

Guinovart, C ;

Espasa, M ;

Bassat, Q ;

Aide, P ;

Ofori-Anyinam, O ;

Navia, MM ;

Corachan, S ;

Ceuppens, M ;

Dubois, MC ;

Demoitié, MA ;

Dubovsky, F ;

Menéndez, C ;

Tornieporth, N ;

Ballou, WR ;

Thompson, R ;

Cohen, J .

LANCET, 2004, 364 (9443) :1411-1420

[3] Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine [J].

Amara, RR ;

Villinger, F ;

Altman, JD ;

Lydy, SL ;

O'Neil, SP ;

Staprans, SI ;

Montefiori, DC ;

Xu, Y ;

Herndon, JG ;

Wyatt, LS ;

Candido, MA ;

Kozyr, NL ;

Earl, PL ;

Smith, JM ;

Ma, HL ;

Grimm, BD ;

Hulsey, ML ;

Miller, J ;

McClure, HM ;

McNicholl, JM ;

Moss, B ;

Robinson, HL .

SCIENCE, 2001, 292 (5514) :69-74

[4] PLGA microspheres containing plasmid DNA: Preservation of supercoiled DNA via cryopreparation and carbohydrate stabilization [J].

Ando, S ;

Putnam, D ;

Pack, DW ;

Langer, R .

JOURNAL OF PHARMACEUTICAL SCIENCES, 1999, 88 (01) :126-130

[5]

[Anonymous], 1994, NOVEL DELIVERY SYSTE

[6] THE INFLUENCE OF ANTIGEN ORGANIZATION ON B-CELL RESPONSIVENESS [J].

BACHMANN, MF ;

ROHRER, UH ;

KUNDIG, TM ;

BURKI, K ;

HENGARTNER, H ;

ZINKERNAGEL, RM .

SCIENCE, 1993, 262 (5138) :1448-1451

[7] Neutralizing antiviral B cell responses [J].

Bachmann, MF ;

Zinkernagel, RM .

ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 :235-270

[8] Oral vaccination in man using antigens in particles: current status [J].

Brayden, DJ .

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 14 (03) :183-189

[9] The preparation, characterization, and evaluation of cationic microparticles for DNA vaccine delivery [J].

Briones, M ;

Singh, M ;

Ugozzoli, M ;

Kazzaz, J ;

Klakamp, S ;

Ott, G ;

O'Hagan, D .

PHARMACEUTICAL RESEARCH, 2001, 18 (05) :709-712

[10] IMMUNE-RESPONSES AND PROTECTION AGAINST BORDETELLA-PERTUSSIS INFECTION AFTER INTRANASAL IMMUNIZATION OF MICE WITH FILAMENTOUS HEMAGGLUTININ IN SOLUTION OR INCORPORATED IN BIODEGRADABLE MICROPARTICLES [J].

CAHILL, ES ;

OHAGAN, DT ;

ILLUM, L ;

BARNARD, A ;

MILLS, KHG ;

REDHEAD, K .

VACCINE, 1995, 13 (05) :455-462

← 1 2 3 4 5 6 7 8 9 10 →